Quarterly report · Q3
4564.TEDINET S100SU6F
Period2023-04-01 → 2023-12-31
Filed2024-02-13
StandardJapan GAAP
ConsolidatedYes
Data checks10 of 10 passed
Key figures · 32
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥466m | 2023-04-01 → 2023-12-31 | Cons. | Net sales |
| Revenue | ¥700m | 2022-04-01 → 2022-12-31 | Cons. | Net sales |
| Operating income | −¥973m | 2023-04-01 → 2023-12-31 | Cons. | Operating income |
| Operating income | −¥905m | 2022-04-01 → 2022-12-31 | Cons. | Operating income |
| Ordinary income | −¥986m | 2023-04-01 → 2023-12-31 | Cons. | Ordinary income |
| Ordinary income | −¥1.1bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥929m | 2022-04-01 → 2022-12-31 | Cons. | Ordinary income |
| Profit before tax | −¥985m | 2023-04-01 → 2023-12-31 | Cons. | Income before income taxes |
| Profit before tax | −¥912m | 2022-04-01 → 2022-12-31 | Cons. | Income before income taxes |
| Net income (owners) | −¥987m | 2023-04-01 → 2023-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥1.1bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥913m | 2022-04-01 → 2022-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | −¥987m | 2023-04-01 → 2023-12-31 | Cons. | Profit loss |
| Net income | −¥913m | 2022-04-01 → 2022-12-31 | Cons. | Profit loss |
| Total assets | ¥931m | at 2023-12-31 | Cons. | Assets |
| Total assets | ¥1.5bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥1.4bn | at 2022-12-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥275m | at 2023-12-31 | Cons. | Liabilities |
| Total liabilities | ¥656m | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥656m | at 2023-12-31 | Cons. | Net assets |
| Net assets / equity | ¥855m | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥1.1bn | at 2022-12-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥599m | at 2023-12-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥1.1bn | at 2023-03-31 | Cons. | Cash and deposits |
| EPS (basic) | ¥-4.68 | 2023-04-01 → 2023-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-1.27 | 2023-10-01 → 2023-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-5.81 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-4.74 | 2022-04-01 → 2022-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-1.55 | 2022-10-01 → 2022-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 62.3% | at 2023-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 51.5% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 68.1% | at 2022-12-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 28
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-12-31 | −¥206,000 |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-12-31 | −¥206,000 |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-12-31 | −¥261m |
| jpcrp040300-q3r_E05363-000Cancer Precision Medical Businessreportable segment | revenue | 2023-04-01 → 2023-12-31 | ¥466m |
| jpcrp040300-q3r_E05363-000Cancer Precision Medical Businessreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥466m |
| jpcrp040300-q3r_E05363-000Cancer Precision Medical Businessreportable segment | segment profit | 2023-04-01 → 2023-12-31 | −¥175m |
| jpcrp040300-q3r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | revenue | 2023-04-01 → 2023-12-31 | ¥634,000 |
| jpcrp040300-q3r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥427,000 |
| jpcrp040300-q3r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥206,000 |
| jpcrp040300-q3r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | segment profit | 2023-04-01 → 2023-12-31 | −¥537m |
| —segment total | revenue | 2023-04-01 → 2023-12-31 | ¥466m |
| —segment total | revenue external | 2023-04-01 → 2023-12-31 | ¥466m |
| —segment total | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥206,000 |
| —segment total | segment profit | 2023-04-01 → 2023-12-31 | −¥712m |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-12-31 | −¥172,000 |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-12-31 | −¥172,000 |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-12-31 | −¥290m |
| jpcrp040300-q3r_E05363-000Cancer Precision Medical Businessreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥691m |
| jpcrp040300-q3r_E05363-000Cancer Precision Medical Businessreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥691m |
| jpcrp040300-q3r_E05363-000Cancer Precision Medical Businessreportable segment | segment profit | 2022-04-01 → 2022-12-31 | −¥79m |
| jpcrp040300-q3r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥9m |
| jpcrp040300-q3r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥9m |
| jpcrp040300-q3r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥172,000 |
| jpcrp040300-q3r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | segment profit | 2022-04-01 → 2022-12-31 | −¥536m |
| —segment total | revenue | 2022-04-01 → 2022-12-31 | ¥700m |
| —segment total | revenue external | 2022-04-01 → 2022-12-31 | ¥700m |
| —segment total | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥172,000 |
| —segment total | segment profit | 2022-04-01 → 2022-12-31 | −¥615m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 312
| Item | Context | Value | Unit |
|---|---|---|---|
| Notes regarding dividend (text) | CurrentYTDDuration | Text · Plus | |
| Notes when there is significant changes in amounts of equity (text) | CurrentYTDDuration | Text · Plus | |
| Notes segment information etc quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | Prior1YTDDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | Prior1YTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | CurrentYTDDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | CurrentYTDDuration | Text · Plus | |
| Notes revenue recognition quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes per share information quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes significant events after reporting period quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | CurrentYTDDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 10 of 10 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |